>>

>>

抑制剂/激活剂

>>

凋亡与自噬

>>

Selisistat EX-527

Selisistat (EX-527) 是一种有效和选择性的 SirT1 (黑腹果蝇中的 Sir2) 抑制剂，IC50 值为 123 nM。Selisistat 缓解多种亨廷顿病动物和细胞模型的病理学。

货号：
TK0205
规格：

1mg

5mg

10mg

25mg
价格：
￥0.00

产品参数

CAS No.	49843-98-3
生物活性	Selisistat (EX-527) is a potent and selective SirT1 (Sir2 in Drosophila melanogaster) inhibitor with an IC50 of 123 nM for SirT1. Selisistat alleviates pathology in multiple animal and cell models of Huntington's disease.
分子式	C13H13ClN2O
分子量	248.71
运输条件	Room temperature in continental US; may vary elsewhere.
储存条件	Powder -20°C 3 years
溶解性数据	DMSO : ≥ 100 mg/mL (402.07 mM)
体内研究	Selisistat (5 and 20 mg/kg, PO, daily; transgenic R6/2 mice beginning at 4.5 weeksof age to death) is protective in the R6/2 mouse model of Huntington’s disease (HD).
体外研究	Selisistat (1-10 μM) inhibits the deacetylation activity of both human SirT1 and Drosophila Sir2 in transfected cells.
文献	•Cell Metab. 2021 Jan 5;33(1):110-127.e5. •Mol Cell. 2020 Jul 16;79(2):304-319.e7. •Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. •Cell Rep. 2020 Aug 4;32(5):107987. •Cell Syst. 2018 Apr 25;6(4):424-443.e7. •Cell Death Dis. 2021 May 18;12(6):501. •J Neuroinflammation. 2021 Dec 10;18(1):287. •Environ Pollut. 2021, 116840. •Int J Biol Macromol. 2018 Dec;120(Pt A):683-692. •J Inflamm Res. 2021 Jul 8;14:3063-3075. •Cell Prolif. 2021 Feb 1;e12991. •Cancers (Basel). 2022, 14(2), 323. •Oxid Med Cell Longev. 2021 Feb 28. •Oxid Med Cell Longev. 2021 Jan 19;2021:6610543. •Oxid Med Cell Longev. 2020 May 16;2020:6384803. •Oxid Med Cell Longev. 2019 Sep 12;2019:5276096. •Biomed Pharmacother. 2021, 111693. •Biomed Pharmacother. 2019 Oct;118:109227. •Eur J Med Chem. 2020 Apr 15;192:112201. •Acta Pharmacol Sin. 2021 Dec 1. •Acta Pharmacol Sin. 2021 Apr 13. •J Nutr Biochem. 2021 Sep 13;108862. •Int J Mol Sci. 2017 May 19;18(5). pii: E1063. •Front Pharmacol. 2020 Sep 11;11:1315. •Front Pharmacol. 2020 Mar 18;11:264. •Front Pharmacol. 2018 Aug 3;9:854. •J Transl Med. 2020 Feb 17;18(1):84. •iScience. 2020 Aug 21;23(8):101431. •J Cell Mol Med. 2021 Mar 10. •J Cell Mol Med. 2020 Nov;24(21):12355-12367. •J Agric Food Chem. 2021 Jul 26. •J Agric Food Chem. 2019 Jun 26;67(25):7157-7166. •Life Sci. 2020 Sep 15;257:118116. •Int Immunopharmacol. 2021, 107600. •Int Immunopharmacol. 2019 Oct;75:105779. •Mol Cell Proteomics. 2019 Mar;18(3):520-533. •Biochim Biophys Acta Mol Cell Res. 2021 Jun 1;119074. •Am J Chin Med. 2020;48(7):1693-1713. •Cell Cycle. 2020 Jul;19(13):1677-1695. •Eur J Pharmacol. 2021 Nov 18;174644. •Eur J Pharmacol. 2019 Oct 15;861:172591. •Molecules. 2019 Aug 25;24(17):3084. •Biochim Biophys Acta. 2018 Mar 6;1863(6):595-603. •Environ Toxicol. 2021 Nov 5. •Int J Mol Med. 2019 Aug;44(2):469-478. •Neurochem Res. 2019 Aug;44(8):1977-1985. •Neurotox Res. 2021 Feb 13. •Biosci Rep. 2018 Dec 21;38(6):BSR20181139. •BMC Immunol. 2021 May 27;22(1):34. •Biochem Biophys Res Commun. 2020 Jul 12;528(1):7-13. •J Mol Neurosci. 2020 Sep 10. •Biochimie. 2020 Mar;170:10-20. •J Pain Res. 2019 Mar 4;12:879-890. •Acta Trop. 2021 May 16;105961. •Mol Med Rep. 2022 Mar;25(3):84. •Biomed Eng Online. 2021 Dec 14;20(1):125. •Metab Brain Dis. 2019 Feb;34(1):203-212. •J Food Biochem. 2021 Jan 24;e13623. •J Cosmet Dermatol. 2021 Apr 24. •Exp Biol Med. 2021 Mar;246(5):596-606. •Thorac Cancer. 2021 Mar 11. •Exp Ther Med. 2020 Dec;20(6):262. •Neuropeptides. 2021, 102134. •Ren Fail. 2021 Dec;43(1):128-140. •J BUON. Nov-Dec 2020;25(6):2665-2671. •Research Square Preprint. 2020 Dec. •Patent. US20180263995A1. •Oncotarget. 2017 Apr 18;8(32):52783-52791.
纯度及产品资料	98%

推荐产品